Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation

Table 2 Clinical outcomes of Non–vitamin K Antagonist Oral Anticoagulants (NOACs) Use Compared With Warfarin Use After Propensity Score Matching

Outcome	NOACs		Warfarin		Hazard Ratio (95% CI)	P value
Outcome	no. of patients with event	no. of 100 patient-years	no. of patients with event	no. of 100 patient-years	Hazard Ratio (95% CI)	P value
Net adverse clinical event	34	25.6	52	32.8	0.74 (0.48–1.14)	0.172
Ischemic stroke or systemic embolism	7	4.9	2	1.1	3.53 (0.78–16.13)	0.102
Major bleeding	29	21.3	51	32.0	0.63 (0.40-1.00)	0.0499
ICH	11	7.7	21	12.2	0.59 (0.28–1.22)	0.155
GI bleeding	12	8.4	19	11.0	0.72 (0.35–1.49)	0.381
All Cause death	100	67.8	98	54.8	1.15 (0.87–1.53)	0.323

ISSN: 1471-2261